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linicians working with depressed patients are
often confronted with the unsatisfactory degree of remis-
sion that current therapeutic strategies yield,and with the
vexing problems of relapse and recurrence.
1 In clinical
medicine,the term “recovery”connotes the act of regain-
ing or returning toward a normal or usual state of health.
However,there is a lack of consensus regarding the use
of this term (which may indicate both a process and a
state),as well as of the related word “remission.”This lat-
ter indicates a temporary abatement of the symptoms of
a disease. Such ambiguities reflect on the concepts of
relapse (the return of a disease after its apparent cessa-
tion) and recurrence (the return of symptoms after a
remission).
In an attempt to overcome these flaws,Frank et al
2 pro-
posed a set of definitions which they referred to as lon-
gitudinal studies of mood disorders,but may entail more
general applicability in psychiatry.Remission (which is
differentiated into partial and full remission) is a rela-
tively brief period during which an improvement of suf-
ficient magnitude is observed and the individual no
longer meets syndromal criteria for the disorder.
Recovery implies a more sustained remission,and raises
the possibility that treatment can be discontinued or
prolonged with the aim of prevention. Relapse is a
return of symptoms satisfying the full syndromal crite-
ria during the period of remission, whereas recurrence
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There is a growing body of literature on residual symp-
toms after apparently successful treatment. The strong
prognostic value of subthreshold symptomatology upon
remission and the relationship between residual and pro-
dromal symptomatology (the rollback phenomenon) have
been outlined. Most residual symptoms also occur in the
prodromal phase of depression and may progress to
become prodromes of relapse. These findings entail
important implications. It is necessary to closely monitor
the patient throughout the different phases of illness and
to assess the quality and extent of residual symptoms. A
more stringent definition of recovery, which is not limited
to symptomatic assessment, but includes psychological
well-being, seems to be necessary. New therapeutic strate-
gies for improving the level of remission, such as treat-
ment of residual symptoms that progress to become pro-
dromes of relapse and/or increasing psychological
well-being, appear to yield more lasting benefits. The
sequential model may provide room for innovative treat-
ment approaches, including the use of drugs for specifi-
cally addressing residual symptoms. As occurs in other
medical disorders (such as diabetes and hypertension), the
active role of the patient in achieving recovery (self-ther-
apy homework) should be pursued.
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these criteria provides helpful ground for decreasing
inconsistencies among research reports, yet it does not
touch some key issues in the conceptualization of these
terms. First, according to these definitions,
2 recovery
occurs when the number and severity of symptoms fall
below the threshold used for defining onset, and this
subthreshold level of symptomatology remains for a
specified period of time. However, this state cannot be
equated with being asymptomatic, and provides room
for a wide range of subclinical conditions. Second, the
definition of remission parallels the traditional medical
concept of convalescence,a transitional period of rein-
tegration after illness.The trajectory of such a process
is thus an important additional dimension which
requires a longitudinal consideration of the develop-
ment of disorders, encompassing the prodromal phase,
the fully developed disorder, and residual states. Not
only the duration of the acute phase of illness—as is
widely acknowledged— may affect the rate of recovery,
but also the characteristics of prodromes,the amount of
residual symptomatology not alleviated by specific
treatments,and the level of premorbid functioning may
influence the course of recovery.
3,4 Finally, the distinc-
tion between recovery and full remission is made on
temporal grounds only.They are not differentiated by
whether active treatment is associated, even though
recovery implies the possibility that therapy can be dis-
continued.A recovered depressed patient who is cur-
rently drug-free is thus equated to another patient who
is receiving long-term, high-dose antidepressant treat-
ment.
The aim of this review is to analyze some issues which
would help to define the psychosocial determinants of
recovery in depression.
The inadequancies of standard 
clinical assessment
The staging method,whereby a disorder is characterized
according to seriousness,extent,and features,has achieved
wide currency in medicine,but is currently neglected in
psychiatry.
4,5The operational definitions of DSM give only
a flat,cross-sectional view of the patient’s depressive ill-
ness,that ignores its longitudinal development,previous
episodes,and responses to previous treatments.
4A prodro-
mal phase can be described in most instances of depres-
sion,
6 and only a minority of patients become asympto-
matic after successful treatment.Current pathophysiolog-
ical models of pathogenesis in depression thus neglect
intermediate phenomenological steps in the balance
between health and disease (Table I).
Staging has the potential to improve the logic and timing
of interventions,just as it does in many complex and seri-
ous medical disorders.
5 Drug mechanisms which may be
operational in the initial phase of treatment may change
during long-term treatment and according to the stages
of illness.
8This approach is also in accordance with the
sequential model of treatment, which was found to be
effective in clinical medicine and psychiatry.
9
The majority of depressed patients do not qualify for one,
but for several,Axis I and Axis II disorders.
10 However,
there is comorbidity which wanes upon successful treat-
ment of depression and comorbidity which persists, in
syndromal or subsyndromal forms (residual symptoms).
Clinical differentiation of such morbidity requires a shift
from the current psychometric model (where severity is
determined by the number of symptoms and not by
intensity or quality) to a clinimetric model,
10-12 which may
allow the definition of the progression,extent,and sever-
ity of depressive illness.
Measurement
Total absence of psychological symptoms is not a fre-
quent characteristic of the general healthy population.
13
As a result, the determination of recovery depends on
the symptom intensity under which recovery is defined,
and on the type and characteristics of the measurements
we select.In the recovery phase symptoms are typically
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Stages
1 Prodromal phase (anxiety, irritable mood, anhedonia, sleep 
disorders)
a. no depressive symptoms
b. minor depression
2 Major depressive episode
3 Residual phase
a. no depressive symptoms
b. dysthymia
4 a. recurrent depression
b. double depression
5 Chronic major depressive episode (lasting at least 2 years 
without interruptions)
Table I. Stages of primary unipolar depression.
7milder than those of the full clinical syndrome.
1 The
capacity of the assessment instrument to measure small
increments or small changes near the normal end of the
spectrum becomes important.The ability of a rating or
self-rating scale to discriminate between different groups
of patients suffering from the same illness (eg,depressed
inpatients and outpatients) and to reflect changes in
experiments in therapeutics such as drug trials in which
the drug effects are small may indicate its degree of sen-
sitivity.
13 This concept is particularly important when
treatment effects are small and in the setting of subclin-
ical symptoms.
1 Unfortunately,researchers tend to focus
on the psychometric characteristics of validity and relia-
bility and to neglect sensitivity.
10,14,15 They may thus
employ inadequately sensitive instruments to establish
lack of significant symptomatology.
The Hamilton Depression Scale (HAM-D)
16 is an exam-
ple of an instrument based on the classical psychometric
model.The key flaw of such an instrument is that the
same score on the Hamilton Rating Scale for Depression
may be the product of few very severe core symptoms
(eg,a severely retarded depressed patient) or of several
mild accessory symptoms (reflecting perhaps a subject
affected by a mild form but with many symptoms and
complaining behavior).Correspondingly,the decrease in
the final score may be ascribed to the improvement/dis-
appearance of the typical depressive signs (eg, mood,
anhedonia, guilt, suicidal ideation, psychic signs, and
retardation),which is significant on clinical grounds,or
to the alleviation of accessory symptoms (eg, anxiety,
appetite, insomnia, sexual interest, and somatic symp-
toms),which is of limited value.Further,adverse effects
of treatments (eg,sleepiness or sedation) may decrease
the total score of the rating scale,producing an artificial
improvement.
15
As important is the target of the instruments employed.
For instance, in a naive conceptualization, yet the one
implicitly endorsed by DSM-III and DSM-IV,well-being
and distress may be seen as mutually exclusive (ie,well-
being is lack of distress).Yet there is evidence to call such
views into question.
17-19As a result,the appraisal of recov-
ery may rest on purely symptomatic grounds,
1 or may be
extended to perceptions (levels of well-being and satis-
faction with life),or be expanded to functional capacity
(the ability to perform activities of daily life,social and
intellectual function,economic status).This latter tridi-
mensional assessment may be subsumed under the rubric
of quality of life.
17
Measurement may also be extended to biological vari-
ables,which tend to subside upon clinical recovery and
may accompany both prodromal and residual symptoma-
tology and constitutes a psychobiological risk for relapse.
Such markers may include abnormalities of the hypothal-
amic-pituitary-adrenal (HPA) axis,
20,21 impaired lympho-
cyte glucocorticoid sensitivity,
22 and abnormal sleep elec-
troencephalographic (EEG) patterns.
23-27
The more sensitive and multidimensional the tools
employed,the more arbitrary the nature of the recovery
which emerges.
Residual symptoms
The notion that the majority of depressed patients expe-
rience mild but chronic residual symptoms or recurrence
of symptoms after complete remission,which was well
delineated in the 1970s,
28 did not receive the attention it
deserved in subsequent years.Such a phenomenon was
emphasized,in fact,mainly in its etiological role regard-
ing dysthymia. Subsyndromal residual symptoms of
major depressive disorder continued to be regarded as
minor fluctuations unworthy of clinical attention.
However,the literature describing the presence of resid-
ual symptoms after completion of drug treatment of
major depression and their clinical implications in terms
of poor long-term outcome continue to grow.
29-43 Residual
subthreshold symptoms were also reported after comple-
tion of psychotherapy.
41,44-46
In 1973 Paykel and associates
47 found social and interper-
sonal maladjustments in recovered depressed patients
compared with controls,despite considerable improve-
ment in social adjustment upon treatment.Submissive
dependency and family attachment improved almost
completely, whereas two other personal dysfunctions,
interpersonal friction and inhibited communication,
showed little change and greatest residual impairment.
47
Residual social maladjustment was subsequently
reported by other investigators,
38,48-52 and was found to
correlate with long-term outcome.
38,48,52-54
The question has been raised as to whether these inter-
personal functioning deficits are trait- or state-depen-
dent.
53,55,56When monthly ratings of impairment in major
life functions and social relationships were obtained dur-
ing a 10-year follow-up of 371 depressed patients,disabil-
ity was pervasive and chronic, but disappeared when
patients became asymptomatic,confirming the hypothe-
sis that psychosocial disability is state-dependent.
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sive symptoms,minor depression/dysthymia,and MDD
represent a continuum of depressive symptom severity
in unipolar MDD,each level of which is associated with
a significant stepwise increment in psychosocial disabil-
ity.
38 In another investigation
52 in 222 depressed outpa-
tients,an earlier onset of clinical response predicted bet-
ter overall psychosocial functioning at end point,whereas
the number and the severity of residual symptoms pre-
dicted poorer overall psychosocial adjustment at end
point in responders.Other studies
53,56 suggested that there
may be a subgroup of patients with impaired psychoso-
cial and/or early onset of depression with stable interper-
sonal deficits.
Similarly,dysfunctional attitudes and attributions were
found to persist after recovery,despite clinical and cog-
nitive improvement.
57-61 These cognitive patterns were
positively correlated with vulnerability to persistent
depression or relapse.
58-60,62These findings were consistent
with the fact that vulnerable attitudes such as high neu-
roticism assessed when the depressed patients are symp-
tomatic predict recovery,
63,64 but that,for the prediction
of relapse,cognitive measures when patients are asymp-
tomatic need to be used.
59 Social maladjustment and dys-
functional attitudes may overlap with characterological
traits assessed after clinical recovery
65-75 or premorbid
personality features.
76,77 Ormel et al
78 studied personality
traits such as neuroticism,low self-esteem,and poor cop-
ing skills, before, during, and after a major depressive
episode,in a 3-wave general population-based investiga-
tion.There was no evidence of a negative change from
premorbid to postmorbid assessment of personality vari-
ables.Postmorbid vulnerability reflected the continua-
tion of premorbid vulnerability.Both were influenced by
prodromal and residual symptoms.
78 Ongur et al
79 found
that temperamental features were related to patterns of
anxiety disorder comorbidity in depressed patients, as
was also found to be the case for well-being.
80
Regardless of the state/trait dichotomy the findings of
different studies indicate that there appears to be a resid-
ual attributional interpersonal component which is
refractory to otherwise successful treatment of depres-
sion.Such components may entail considerable predic-
tive value.
Methodological problems in assessment of residual
symptoms,however,emerge.There is paucity of psycho-
metric studies addressing the phenomenology of
depressed patients after benefiting from treatment.
Recovered depressed patients displayed significantly
more depression and anxiety than control subjects in one
study,
81 but not in another.
82 Differences in the sensitivity
of the rating scales which were employed may account
for such discrepant results. Using Paykel's
83 Clinical
Interview for Depression,only 6 (12.2%) of 49 patients
with major depression successfully treated with antide-
pressant drugs and judged to be fully remitted had no
residual symptoms.
84The majority of residual symptoms
were present also in the prodromal phase of illness.The
most frequently reported symptoms involved anxiety and
irritability.This findings were consistent with previous
studies on prodromal symptoms of depression,
85,86 over-
lapped with results concerned with interpersonal fric-
tion,
47 irritability,
77 and anxiety
65 and underwent indepen-
dent replication.Using a similar methodology,Paykel et
al,
34 in fact, found residual symptoms to be present in
32% of 60 patients who remitted from major depression.
Previous diagnosis of dysthymia did not predict residual
symptoms.Depressed mood,guilt,hopelessness,impaired
work and interest,anxiety,and anorexia were identified
by the Clinical Interview for Depression.
36These symp-
toms tended to persist at 8- to 10-year follow-up.
87
Nierenberg et al
37 found that only 18% of full responders
to fluoxetine were free of residual symptoms.Gastò et
al
39 reported the same percentage in elderly patients with
major depressive disorders.Judd et al
88 found that incom-
plete recovery from the first lifetime major depressive
episode was linked to a chronic course of illness during a
12-year prospective naturalistic follow-up.Angst et al
89
observed that clinical trials overestimate the likelihood
of full recovery on a single antidepressant. The usual
response rates of 60% to 70% are typically reported
when a reduction of 50% or more in the Hamilton
Depression Rating Scale occurs.However,using a more
conservative score for defining response, only 45% of
approximately 900 depressed patients achieved a satis-
factory response.Cornwall and Scott
90 reviewed publica-
tions relating to a precise definition of partial remission.
1
Partial remission was found to affect at least one third of
subjects treated for depression,to increase the risk of fur-
ther depressive relapse,and to adversely affect social and
work performance.In a large,multicenter trial involving
2876 outpatients receiving flexible doses of citalopram,
only 28% of subjects were found to have remitted.
91
In conclusion, substantial residual symptomatology
appears to characterize depressed patients who success-
fully responded to pharmacological or psychological
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464therapies.Anxiety,irritability,and interpersonal friction,
in addition to specific depressive symptoms,appear to be
common residual symptoms.
The rollback phenomenon and 
state-trait dichotomy
Detre and Jarecki
92 provided a model for relating prodro-
mal and residual symptomatology,defined as the rollback
phenomenon:as the illness remits,it progressively reca-
pitulates (though in a reverse order) many of the stages
and symptoms that were seen during the time it devel-
oped.According to the rollback model, there is also a
temporal relationship between the time of development
of a disorder and the duration of the phase of recovery.
For example, if an illness begins with occasional anxiety
attacks that are superseded some weeks later by depressive
symptoms which then become progressively more severe
until,after several months,the patient develops total insom-
nia and confusion, the symptoms tend, as the condition
improves, to remit in reverse order, the confusion and
insomnia diminishing first,and the depressed mood next.
After the depression lifts,the patient may again experience
anxiety attacks for several weeks,until finally these symp-
toms,too,disappear."
92
The rollback phenomenon—or, at least, a strong rela-
tionship between prodromal and residual symptomatol-
ogy—has been substantiated in the treatment of major
depression.
84 In one study,
84 almost 70% of the residual
symptoms that were found to occur in 40 remitted
depressed patients were also present at the prodromal
phase of illness. This percentage increased to almost
90% of cases for residual generalized anxiety and irri-
tability.These results achieved independent replication,
93
and are also supported by several lines of evidence.In a
prospective study
94 which examined the possibility that
episodes of major depression result in lasting personal-
ity changes that persist beyond recovery (the scar
hypothesis), there was no evidence of negative change
from premorbid to postmorbid assessment.These find-
ings were replicated by Ormel et al.
78 Further,a 10-year
follow-up study after severe depression
93 suggested that
residual symptoms were common and persistent,with
considerable fluctuations.This would suggest continu-
ity—whether we rate it in characterological or sympto-
matological terms—between the prodromal and resid-
ual phases. Another line of evidence is based on
recognition of specific temporal courses of change dur-
ing treatment of depression.
96-99 Different types of treat-
ment may affect the temporal course of change in
depression,
100 and the use of pattern analysis may differ-
entiate true drug and placebo responses early in treat-
ment.
101 Patients do not suddenly become well,but tend
to gradually lose their depressive symptoms over the
months following treatment.
102 Stassen and associates
103
found that the time course of improvement among
responders to amitriptyline, oxaprotiline, and placebo
was independent of the treatment modality, and thus
identical in all three groups. Once triggered, the time
course of recovery from illness became identical to the
spontaneous remissions on placebo. Antidepressant
drugs,therefore,may not change the pattern of the nat-
ural course of recovery from illness,but simply speed the
recovery and change the boundary between "respon-
ders" and “nonresponders.”
103
The psychometric distinction between state and trait may
also reflect the rollback phenomenon,and may hinder
detection of change.If recovery implies the return to pre-
morbid functioning,personality traits are likely to influ-
ence its definition. Unfortunately, the state-trait
dichotomy and its psychometric counterparts appear to
be situated on a continuum with blurred borders which
do not permit clearcut differentiation.
1 For instance,cer-
tain personality traits may entail enduring, long-term
characteristic modes of feeling,thinking,and behaving in
the course of depression,whereas antidepressant treat-
ment may be beneficial in the modification of certain
personality traits, which are therefore subject to state
influences.
68,69 Rafanelli et al
18 introduced the hypothesis
that the state/trait characteristics of a specific instrument
may be stage-dependent.
The concept of mental health
Ryff and Singer
104 remark that,historically,mental health
research is dramatically weighted on the side of psycho-
logical dysfunction,and that health is equated with the
absence of illness rather than the presence of wellness.
They suggest that the absence of well-being creates con-
ditions of vulnerability to possible future adversities,and
that the route to recovery lies not exclusively in alleviat-
ing the negative,but in engendering the positive.Little is
known of the relationship between subclinical symptoms
and well-being in the residual phase of affective disor-
ders.In a small investigation,
105 a well-being-enhancing
psychotherapeutic strategy (well-being therapy) was
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465found to be associated with a significant reduction in
residual symptoms in patients with affective disorders.
The balance between positive and negative affects and
its biological counterparts may thus carry considerable
weight on the complex regulation underlying the long-
term outcome of affective disorders.
In a survey on factors identified by depressed outpa-
tients as important in determining remission, the most
frequently judged as such were the presence of features
of positive mental health, such as optimism and self-
confidence, a return to one’s usual, normal self, and a
return to the usual level of functioning.
106 In 1958 Marie
Jahoda
107 outlined some tentative criteria for positive
mental health, encompassing attitudes toward the self,
growth,integration,autonomy,perception of reality,and
environmental mastery. Such criteria were refined and
expanded in Carol Ryff’s multidimensional model,
108
which encompasses six dimensions:mastery of the envi-
ronment,personal growth,purpose and meaning of life,
autonomy, self-acceptance, and positive relationships.
This theoretical model of psychological well-being was
then applied in a variety of clinical settings.
109 Ryff’s psy-
chological dimensions
108 may be instrumental in assess-
ing both the process and the definition of recovery
(Table II).
The neglect of self-therapy
An increasing body of evidence links the progression of
several medical disorders to specific lifestyle behaviors.
110
Half of the deaths that take place in the US can be attrib-
uted to “largely preventable behaviors and exposures,”
such as tobacco smoking,obesity,and physical inactiv-
ity.
111 Similarly recovered depressed patients continue to
show social and interpersonal maladjustments and dys-
functional attitudes which have serious consequences in
terms of vulnerability to persistent depression or relapse.
Unfortunately,psychiatrists tend to view treatment and
prevention of relapse of depression purely in pharmaco-
logical terms,and they overemphasize the need for pro-
viding maintenance therapies,without paying attention
to lifestyle and problems related to tolerance.
8,112
Frank and Frank
113 have clarified how “certain types of
therapy rely primarily on the healer’s ability to mobilize
healing forces in the sufferer by psychological means.
These forms of treatment may be generically termed psy-
chotherapy.”
Cognitive behavioral therapy may be seen as guided self-
therapy which aims at developing the patient’s control
over his or her own problems or behaviours.
114 Homework
assignments (whether consisting of self-observation or
Clinical research
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Dimensions Optimal level
Environmental mastery A: Has a sense of mastery and competence in managing the environment
B: Makes effective use of surrounding opportunities
C: Is able to create or choose contexts suitable to personal needs and values
Personal growth A: Has a feeling of continued development
B: Has sense of realizing own potential
C: Sees improvement in self and behavior over time
Purpose in life A: Has goals in life and a sense of direction
B: Feels there is meaning to present and past life
C: Holds beliefs that give life purpose
Autonomy A: Is self-determining and independent
B: Is able to resist social pressures
C: Evaluates self by personal standards
Self-acceptance A: Has a positive attitude toward self
B: Accepts his or her good and bad qualities
C: Feels positive about his past life
Positive relations with others A: Has warm and trusting relationships with others
B: Is capable of strong empathy, affection, and intimacy
C: Understands give and take of human relationships
Table II. Modification of the 6 dimensions of psychological well-being according to Ryff’s model.
108
Note: At least A or B or C should be present to satisfy criteria for each dimension.performing specific tasks) are given and reviewed by the
therapist.
The patient’s contribution to obtaining recovery has been
traditionally outlined in anxiety disorders,
115,116 with par-
ticular reference to self-exposure.More recently,a num-
ber of psychological strategies have been developed for
prevention of relapse in depressive disorders. They
include cognitive restructuring and increase in of coping
skills,
117-120 promotion of psychological well-being,
105,117
mindfulness meditation,
121 lifestyle modification.
117The
optimal application of these therapies has taken place
within the sequential model of therapy.
9
The sequential model
There is increasing literature on the bleak long-term out-
come of depression as to relapse and recurrence.
122-129This
unsatisfactory outcome seems to be associated with the
presence of substantial residual symptomatology,which
are probably the most consistent predictors of relapse.In
a large cohort study,asymptomatic recoverers relapsed
in 157 weeks, compared with residual recoverers who
relapsed in about 28 weeks.
35At the same time,there is
growing awareness of the fact that current forms of treat-
ment seem to be insufficient for many patients,both in
adult
91,130 and adolescent
131 depression.Increasing the level
of remission thus appears to play a key role for yelding
optimal treatment outcome.
If residual symptoms are the rule after completion of
drug or psychotherapeutic treatment and their presence
has been correlated with poor outcome,residual symp-
toms upon recovery may progress to become prodromal
symptoms of relapse and treatment directed toward
residual symptoms may yield long-term benefits.
1
Treatments which are administered in a sequential order
(psychotherapy after pharmacotherapy,psychotherapy
followed by pharmacotherapy, one drug following
another,and one psychotherapeutic treatment following
another) may be more successful in increasing the spec-
trum of therapy and in yielding disappearance of resid-
ual symptomatology.
9There is a substantial body of evi-
dence supporting the use of cognitive behavioral therapy
after successful pharmacotherapy for decreasing the like-
lihood of relapse during follow-up.
84,117,118,132-138 In two stud-
ies
132,133 follow-up was up to 6 years.
The rationale of this approach was to spend cognitive
behavioral treatment resources when they are most likely
to make a unique and separate contribution to patient well-
being and to achieve a more pervasive recovery.Weissman
and associates
139 showed a significant effect of interpersonal
psychotherapy on social adjustment symptoms of depres-
sive patients,whereas there was no effect on the patient’s
social adjustment for amitriptyline and there were no drug-
psychotherapy interactions. Since social adjustment is a
major part of residual symptomatology in depression,as
described previously,the findings of this study may now be
reinterpreted according to a sequential, stage-oriented
model,
4 where different therapeutic strategies can be
applied to different stages of illness.
There has been little research on other forms of sequen-
tial treatment in depression.
9 It has been suggested that
the most effective drugs in treating acute depression may
not be the most suitable for postacute or continuation
treatment.
140 During a 6-year follow-up of a randomized
trial comparing the sequential use of pharmacotherapy
and cognitive behavioral treatment versus clinical man-
agement in patient with recurrent depression,
134 no anti-
depressant drugs were used unless a relapse ensued.
Patients were then treated with the same antidepressant
drug that had been used in the previous episode.
Clonazepam was added to the treatment regimen and
continued when the antidepressant drug was stopped.
The mean survival time after introduction of clonazepam
was significantly longer than the one before the first
relapse.Menza et al
141 have postulated the sequential use
of antidepressants and drugs which may specifically
improve fatigue,sexual dysfunction,anxiety,and sleep
disturbances.
On the contrary,the effect sizes favoring combined treat-
ment have been generally rather modest.
142,143 One study
that specifically addressed the effect of combined treat-
ment (imipramine plus interpersonal psychotherapy) ver-
sus each treatment alone or no active treatment (upon
the levels of residual symptoms) revealed no significant
differences among the four strategies.
41 Patients in the
combined treatment group,however,had fewer symptom
peaks during the maintenance phase.
The definition of recovery
A basic problem in the criteria developed by Frank and
associates
2 is the lack of criteria for judging a patient to
be asymptomatic.The fact that a patient no longer meets
syndromal criteria is insufficient and the number and
quality of minimal symptoms allowed are not specified.
Not all symptoms are equally important.
14,15 For instance,
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467persistence of depressed mood is different from lack of
concentration in an improved depressed patient.Often
different treatments are generally compared on the rate
of response they may yield, instead of the amount of
residual symptomatology they may leave.Unfortunately,
currently used scales for assessing treatment outcome,
such as the Hamilton Depression Rating Scale,are inad-
equate for assessing the wide spectrum of residual symp-
tomatology.
6 Further, the concept of recovery should
involve psychological well-being.
1 Finally,Frank and asso-
ciates
2 emphasized the connection between the declara-
tion of recovery and the possibility that treatment can be
discontinued or prolonged only for preventive purposes.
The symptomatic state of patients who are drug-free
could be equated,in this case,to that of patients receiv-
ing continuation therapy. As a result, the criteria for
recovery
2 seem to need a multidimensional redefinition,
which reflects the clinician's orientation and prognosis,
aside from a symptomatic assessment. Fava and col-
leagues
1 have recently suggested a new set of criteria for
defining recovery that encompass psychological well-
being (Table III).
Commonly, the concept of recovery reflects that of
“improvement”which refers to the clinical distance along
which the current state of the patient is compared with
the pretreatment position.In this sense,recovery can be
expressed either as a categorical variable (present/absent)
or as a comparative category (nonrecovered, slightly
recovered, moderately recovered, greatly recovered).
Both expressions require arbitrary cutoff points related
to the amount of improvement.A depressed patient who,
when asked how he or she feels after 3 weeks of treat-
ment replies “just fine”(instead of “better”),uses a self-
monadic component.The amount of change induced by
treatment,however,may make him/her overlook the dis-
tance from an intended goal,such as the pre-episode state.
The physician may collude with the patient in this illusion
of wellness, since he/she may be gratified more by the
amount of improvement induced in the patient,than by
the current distance from an intended goal.
1 Clinicians
may choose recovery as a target that is negotiated
between the doctor and the patient.The doctor can insist
that the target be reasonable (eg,not asking to be better
than before the illness).Nevertheless,the idea of success-
ful recovery may differ from one patient to the next and
should not be constrained too much by the doctor’s ideas.
We should accept the possibility that a treatment may
determine abatement of symptoms in some patients,leave
a substantial residual symptomatology in others,yield an
unsatisfactory response in others,and provide no benefit,
or even cause harm,in a few.The type of residual symp-
tomatology varies widely from patient to patient and
needs to be assessed individually.
8
Conclusions
The literature surveyed in this paper suggests that stan-
dard treatment of depression,even in specialized settings,
seems to yield modest and temporary benefits and to
leave a large amount of residual symptomatology,which
appears to be one of the the strongest predictors of unfa-
vorable outcome.Increasing the level of remission thus
appears to play a key role in yielding an optimal treat-
ment outcome.It is hoped that more stringent criteria for
recovery and endorsement of a longitudinal appraisal of
affective disturbances may result in therapeutic efforts
yielding more lasting relief. ❏
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Recovery from a major depressive episode is defined to occur
when:
• the patient remains in full remission despite discontinuation of 
treatment (whether pharmacological or psychotherapeutic)
• if subclinical or subsyndromal symptoms are present, these are 
judged to be likely to improve spontaneously over time or not 
to affect the course of the illness. Residual symptoms which 
occurred also in the prodromal phase of illness are unlikely 
to be devoid of clinical implications
• the patient reports psychological well-being in at least one of 
the six areas described in Ryff’s model.
108
Table III. Definition of recovery.
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